Read Our News And Press Releases

Read our news and press releases

As a business striving for growth, Halberd is rapidly changing. This means that we have many stories to tell, we like to share them with you.

Jul 24 2024

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

By Admin|2024-07-23T18:32:56-04:00July 24th, 2024|Featured, Investor News, Press Releases|0 Comments

Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented, “In the early ...

May 22 2024

Halberd/Athena GTX Research Promises a Much Brighter Future

By Admin|2024-05-21T16:43:28-04:00May 22nd, 2024|Featured, Investor News, News, Press Releases, Technology|0 Comments

Walt Disney once said, “All our dreams can come true if we have the courage to pursue them”. Jackson Center, PA May 22, 2024 – Halberd Corporation (OTC-PINK: "HALB”) in cooperation with Athena GTX, Inc is standing at the threshold of some major advancements to treat the issues facing not only our military but people ...

May 9 2024

Halberd’s Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill

By Admin|2024-05-08T18:15:45-04:00May 9th, 2024|Featured, Investor News, News, Press Releases|0 Comments

Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. Jackson Center, PA, May 9, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) two active programs for the treatment and mitigation of the negative effects of traumatic brain injury (TBI) align well with the newly passed bill in ...

Apr 30 2024

Halberd’s Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans

By Admin|2024-04-29T18:57:39-04:00April 30th, 2024|Featured, Investor News, Medical, News, Press Releases|0 Comments

LDN+ Drug Designed to Combat PTSD and Suicidal Ideation Jackson Center, PA, April 30, 2024 – Halberd Corporation (OTC-PINK: "HALB”) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot ...

Apr 4 2024

Halberd’s Patented Drug, LDN+, the Subject of a Limited Clinical Trial under an Innovative Four-company Cooperative Research and Development (CRADA) Contract.

By Admin|2024-04-04T17:47:08-04:00April 4th, 2024|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, April 4, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just ...

Feb 8 2024

Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing

By Admin|2024-02-08T08:07:03-05:00February 8th, 2024|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA February 8, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed ...

Feb 7 2024

Halberd’s Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on “The Street Reports Podcast”

By Admin|2024-02-07T17:33:32-05:00February 7th, 2024|Investor News, News, Press Releases|0 Comments

JACKSON CENTER, PA February 6, 2024 -- Halberd Corporation’s (OTC: HALB) and Athena GTX’s executives interviewed on "The Street Reports," discuss the relationship between Halberd and Athena and why that relationship is going to advance Halberd’s breakthrough technologies toward government contracts. Listen here: https://thestreetreports.com/halb-ceo-william-hartman-cto-dr-mitchell-felder-and-ceo-of-athena-gtx-mark-darrah-discuss-company-partnership-and-optimistic-2024-on-the-street-reports-podcast-listen-now/ To get the latest on Halberd’s exciting developments, subscribe by submitting ...

Jan 9 2024

Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX

By Admin|2024-01-10T05:12:05-05:00January 9th, 2024|Featured, Investor News, Press Releases|0 Comments

Athena will employ its successful history of securing government contracts, spearheading such initiatives Jackson Center, PA January 9, 2024 – Halberd Corporation (OTC-PINK: "HALB”) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions ...

Dec 13 2023

Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com

By Admin|2023-12-12T18:17:31-05:00December 13th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to move Halberd forward Jackson Center, PA December 13, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd’s patented low dose naltrexone ...

Nov 15 2023

Halberd Corporation Plans to Extend Research Partnership with Mississippi State University

By Admin|2023-11-14T18:09:30-05:00November 15th, 2023|Featured, Investor News, News, Press Releases|0 Comments

MSU Research for Halberd to Transcend the TBI Nasal Spray Jackson Center, PA November 15, 2023 – Halberd Corporation (OTC-PINK: "HALB”) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent ...

Previous 123 Next